BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18717827)

  • 1. Dasatinib inhibits progenitor cell proliferation from polycythaemia vera.
    Wappl M; Jaeger E; Streubel B; Gisslinger H; Schwarzinger I; Valent P; Oehler L
    Eur J Clin Invest; 2008 Aug; 38(8):578-84. PubMed ID: 18717827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib effect on growth and signal transduction in polycythemia vera.
    Gaikwad A; Verstovsek S; Yoon D; Chang KT; Manshouri T; Nussenzveig R; Cortes J; Vainchenker W; Prchal JT
    Exp Hematol; 2007 Jun; 35(6):931-8. PubMed ID: 17533047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.
    Gaikwad A; Nussenzveig R; Liu E; Gottshalk S; Chang K; Prchal JT
    Exp Hematol; 2007 Apr; 35(4):587-95. PubMed ID: 17379069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycythemia vera: scientific advances and current practice.
    Tefferi A; Spivak JL
    Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
    J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cells from patients with polycythemia vera elaborate growth factors which contribute to endogenous erythroid and megakaryocyte colony formation.
    Ishii T; Zhao Y; Shi J; Sozer S; Hoffman R; Xu M
    Leukemia; 2007 Dec; 21(12):2433-41. PubMed ID: 17713553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycythemia vera is not initiated by JAK2V617F mutation.
    Nussenzveig RH; Swierczek SI; Jelinek J; Gaikwad A; Liu E; Verstovsek S; Prchal JF; Prchal JT
    Exp Hematol; 2007 Jan; 35(1):32-8. PubMed ID: 17198871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.
    Boissinot M; Cleyrat C; Vilaine M; Jacques Y; Corre I; Hermouet S
    Oncogene; 2011 Feb; 30(8):990-1001. PubMed ID: 21042281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
    Manshouri T; Quintás-Cardama A; Nussenzveig RH; Gaikwad A; Estrov Z; Prchal J; Cortes JE; Kantarjian HM; Verstovsek S
    Cancer Sci; 2008 Jun; 99(6):1265-73. PubMed ID: 18482053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera.
    Nagao T; Kurosu T; Umezawa Y; Nogami A; Oshikawa G; Tohda S; Yamamoto M; Miura O
    PLoS One; 2014; 9(1):e84746. PubMed ID: 24404189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.
    Menier C; Guillard C; Cassinat B; Carosella ED; Rouas-Freiss N
    Leukemia; 2008 Mar; 22(3):578-84. PubMed ID: 18059484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An inhibitor of Janus kinase 2 prevents polycythemia in mice.
    Mathur A; Mo JR; Kraus M; O'Hare E; Sinclair P; Young J; Zhao S; Wang Y; Kopinja J; Qu X; Reilly J; Walker D; Xu L; Aleksandrowicz D; Marshall G; Scott ML; Kohl NE; Bachman E
    Biochem Pharmacol; 2009 Aug; 78(4):382-9. PubMed ID: 19413997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of two tyrosine kinase inhibitors on growth and signal transduction in polycythemia vera.
    Gaikwad A; Prchal JT
    Exp Hematol; 2007 Nov; 35(11):1647-56. PubMed ID: 17976517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients.
    Besses C; Alvarez-Larrán A; Martínez-Avilés L; Mojal S; Longarón R; Salar A; Florensa L; Serrano S; Bellosillo B
    Br J Haematol; 2011 Feb; 152(4):413-9. PubMed ID: 21219298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm.
    Barrio S; Gallardo M; Arenas A; Ayala R; Rapado I; Rueda D; Jiménez-Ubieto A; Albizua E; Burgaleta C; Gilsanz F; Martinez-Lopez J
    Br J Haematol; 2013 Jun; 161(5):667-676. PubMed ID: 23560534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.
    Hexner E; Roboz G; Hoffman R; Luger S; Mascarenhas J; Carroll M; Clementi R; Bensen-Kennedy D; Moliterno A
    Br J Haematol; 2014 Jan; 164(1):83-93. PubMed ID: 24903629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors.
    Hiwase DK; White DL; Powell JA; Saunders VA; Zrim SA; Frede AK; Guthridge MA; Lopez AF; D'Andrea RJ; To LB; Melo JV; Kumar S; Hughes TP
    Leukemia; 2010 Apr; 24(4):771-8. PubMed ID: 20130598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.